Ventyx Biosciences (VTYX) Competitors $2.63 -0.17 (-6.07%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.75 +0.12 (+4.52%) As of 08/1/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTYX vs. LENZ, NRIX, URGN, NUVB, SION, SNDX, QURE, DNA, IMTX, and ANABShould you be buying Ventyx Biosciences stock or one of its competitors? The main competitors of Ventyx Biosciences include LENZ Therapeutics (LENZ), Nurix Therapeutics (NRIX), Urogen Pharma (URGN), Nuvation Bio (NUVB), Sionna Therapeutics (SION), Syndax Pharmaceuticals (SNDX), uniQure (QURE), Ginkgo Bioworks (DNA), Immatics (IMTX), and AnaptysBio (ANAB). These companies are all part of the "pharmaceutical products" industry. Ventyx Biosciences vs. Its Competitors LENZ Therapeutics Nurix Therapeutics Urogen Pharma Nuvation Bio Sionna Therapeutics Syndax Pharmaceuticals uniQure Ginkgo Bioworks Immatics AnaptysBio Ventyx Biosciences (NASDAQ:VTYX) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Does the media prefer VTYX or LENZ? In the previous week, LENZ Therapeutics had 28 more articles in the media than Ventyx Biosciences. MarketBeat recorded 32 mentions for LENZ Therapeutics and 4 mentions for Ventyx Biosciences. Ventyx Biosciences' average media sentiment score of 0.94 beat LENZ Therapeutics' score of 0.63 indicating that Ventyx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ventyx Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LENZ Therapeutics 8 Very Positive mention(s) 6 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer VTYX or LENZ? Ventyx Biosciences presently has a consensus target price of $10.00, indicating a potential upside of 280.23%. LENZ Therapeutics has a consensus target price of $49.60, indicating a potential upside of 65.55%. Given Ventyx Biosciences' higher probable upside, research analysts clearly believe Ventyx Biosciences is more favorable than LENZ Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ventyx Biosciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Is VTYX or LENZ more profitable? LENZ Therapeutics' return on equity of -25.63% beat Ventyx Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Ventyx BiosciencesN/A -47.45% -43.49% LENZ Therapeutics N/A -25.63%-24.43% Which has preferable valuation and earnings, VTYX or LENZ? LENZ Therapeutics is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVentyx BiosciencesN/AN/A-$135.12M-$1.75-1.50LENZ TherapeuticsN/AN/A-$49.77M-$1.90-15.77 Do institutionals & insiders have more ownership in VTYX or LENZ? 97.9% of Ventyx Biosciences shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 14.5% of Ventyx Biosciences shares are held by insiders. Comparatively, 6.9% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, VTYX or LENZ? Ventyx Biosciences has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. SummaryVentyx Biosciences and LENZ Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Ventyx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTYX vs. The Competition Export to ExcelMetricVentyx BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$187.15M$3.01B$5.52B$9.37BDividend YieldN/A2.44%4.74%4.12%P/E Ratio-1.5017.7428.9323.80Price / SalesN/A309.13440.5196.33Price / CashN/A41.6335.0756.59Price / Book0.738.488.255.54Net Income-$135.12M-$55.06M$3.25B$259.97M7 Day Performance-17.30%-3.99%-3.75%-4.67%1 Month Performance25.00%8.53%2.99%3.29%1 Year Performance26.44%6.51%25.34%17.92% Ventyx Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTYXVentyx Biosciences2.7666 of 5 stars$2.63-6.1%$10.00+280.2%+26.4%$187.15MN/A-1.5030News CoverageShort Interest ↑LENZLENZ Therapeutics1.6679 of 5 stars$31.51-0.3%$48.60+54.2%+24.7%$889.98MN/A-17.80110Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionNRIXNurix Therapeutics2.6611 of 5 stars$11.93+3.6%$29.31+145.7%-46.9%$880.69M$88.38M-4.57300News CoverageAnalyst ForecastURGNUrogen Pharma4.6196 of 5 stars$18.90-0.3%$32.86+73.8%+23.7%$875.52M$90.40M-5.94200News CoverageInsider TradeNUVBNuvation Bio2.2397 of 5 stars$2.55+2.0%$7.17+181.0%-33.9%$850.66M$7.87M-1.0960News CoverageUpcoming EarningsSIONSionna TherapeuticsN/A$19.85+3.9%$38.50+94.0%N/A$842.78MN/A0.0035Positive NewsLockup ExpirationSNDXSyndax Pharmaceuticals3.5578 of 5 stars$9.57-0.6%$34.10+256.3%-52.6%$828.64M$23.68M-2.48110Upcoming EarningsQUREuniQure2.4193 of 5 stars$14.98-0.9%$37.82+152.5%+87.3%$827.66M$27.12M-3.41500Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionDNAGinkgo Bioworks1.1785 of 5 stars$13.94-0.1%$8.50-39.0%N/A$817.10M$227.04M-1.52640News CoverageUpcoming EarningsGap DownIMTXImmatics2.1578 of 5 stars$6.67+1.7%$14.67+119.9%-44.2%$797.37M$168.65M-39.23260ANABAnaptysBio2.2021 of 5 stars$26.59-1.3%$47.13+77.2%-24.6%$791.51M$91.28M-5.48100News CoverageUpcoming Earnings Related Companies and Tools Related Companies LENZ Therapeutics Competitors Nurix Therapeutics Competitors Urogen Pharma Competitors Nuvation Bio Competitors Sionna Therapeutics Competitors Syndax Pharmaceuticals Competitors uniQure Competitors Ginkgo Bioworks Competitors Immatics Competitors AnaptysBio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTYX) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ventyx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VTYX Stock Alerts